Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

By D. Schadendorf, F. Hodi, C. Robert, Jeffrey S. Weber, K. Margolin, O. Hamid, D. Patt, Tai-Tsang Chen, D. Berman, J. Wolchok. Journal of Clinical Oncology, 2015

1,993 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/56060790fbd10e780f6b76ce2e9547cd717bba82

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance (2017, background): “However, durable clinical responses are observed in only a minority of patients treated with singleagent cytotoxic T lymphocyte antigen–4 (CTLA-4) (1) or programmed death receptor–1 (PD-1) blockade (2, 3).”
Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade (2016, background): “Analysis of long-term data of patients who received anti-CTLA-4 antibodies in unresectable or metastatic melanoma shows a plateau in the survival curve after 3 years (Schadendorf et al., 2015), suggesting curative potential.”
A systematic review and network meta‐analysis of immunotherapy and targeted therapy for advanced melanoma (2017, background): “Those findings seem to embody the preliminary reports of prolonged disease control under immunotherapy [5].”
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017, background): “Of note, approximately 20% of ipilimumabtreated patients with melanoma experienced long-term survival.(17,18,20-26) Results of a phase I/II dose-finding study of ipilimumab in 71 chemotherapy-naive or chemotherapy-pretreated patients with metastatic CRPC (mCRPC) showed antitumor activity in this cli”
PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Ipilimumabmonotherapy produces clinical responses in 10 to 20% of patients and extends overall survival in metastatic melanoma, with 20% of patients surviving 3 years or longer (123, 124).”
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “ability to modualte the immune system to attack melanoma cancer cells [25].”